FDA Selects Dexcom for Innovative Health Tech Pilot Program
On July 27, 2026, the Food and Drug Administration (FDA) revealed that Dexcom’s glucose monitoring software has been chosen as the inaugural participant in its Technology-Enabled Meaningful Patient Outcomes (TEMPO) program. This initiative is designed to enhance patient care by integrating advanced technology into health management, particularly for seniors. Michelle Tarver, head of the FDA’s medical device center, emphasized the significance of this selection, stating that it marks a pivotal moment in the FDA's collaboration with the Centers for Medicare & Medicaid Services (CMS) Innovation Center to gather real-world evidence that demonstrates the effectiveness of these technologies in meeting patient needs. Dexcom, a prominent player in healthcare technology, has developed a system that merges data from its G7 and Stelo sensors with additional health metrics, including sleep patterns, nutritional intake, and stress levels. This comprehensive approach aims to provide users with personalized health insights that can aid in managing blood sugar levels more effectively. Jake Leach, president and CEO of Dexcom, noted that by transforming glucose data into actionable insights, the technology could empower millions to make significant lifestyle changes before the onset of serious health conditions. The TEMPO program is part of a broader strategy to encourage the adoption of health technologies that can improve outcomes for chronic conditions such as diabetes, hypertension, and depression. It allows up to forty technologies to bypass certain medical device regulations and receive Medicare reimbursements when prescribed by doctors for senior patients. This initiative, along with the ACCESS model launched on July 5, aims to provide seniors with a range of technological solutions, from AI-generated dietary recommendations to guided meditation resources, ultimately fostering better health management and quality of life for older adults.




